Cancer

Led by Sisi He from the Erik Nelson lab, researchers have found that a metabolite of cholesterol (27-hydroxycholesterol; 27HC) was essential for the growth of ovarian tumors in mice.

The latest paper by the Shapiro lab looks at the effect of mutations in the estrogen receptor on the growth and spread of breast cancer cells. The findings were published in a paper titled "Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells...

Professor Kannanganattu Prasanth led a team that found that certain genes that don’t code for proteins could play an important regulatory role in breast cancer.

Discovery provides deeper insight into DNA and the fight against cancer.

The Prasanths began a new life as postdoctoral researchers at Cold Spring Harbor Laboratory in New York. And today, as University of Illinois CDB professors, they continue to work side by side — literally. Their respective labs are next to each other in the Chemical and Life Sciences Building...

Prasanth’s lab published several papers on a particular lncRNA called MALAT1, with significant findings showing an important link between cancer and MALAT1. They found that when MALAT1 is overexpressed in breast cells, the cells form tumors. Conversely, when it is depleted in breast cancer cells,...

The Kranz lab and colleagues have recently publish a trio of papers that describe the engineering of receptors that can mediate specific and potent destruction of cancers by T cells.

For decades, MCB and the University of Illinois have been at the forefront of understanding the role of estrogen and the estrogen receptor (ER) in causing breast cancer. This is essential work: Breast cancer is the most commonly diagnosed cancer in women, affecting roughly one in eight women in the...

Benita Katzenellenbogen has delved into the causes and treatments for breast cancer and other hormone-dependent cancers for virtually her entire career. Her tireless work in the field has established her as a world-renowned expert.

The study, reported in Nature Communications, identifies new potential drug targets that could inhibit the creation or actions of the dangerous cholesterol byproduct.